moxifloxacin has been researched along with chlorhexidine in 3 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (chlorhexidine) | Trials (chlorhexidine) | Recent Studies (post-2010) (chlorhexidine) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 9,521 | 2,099 | 3,952 |
| Protein | Taxonomy | moxifloxacin (IC50) | chlorhexidine (IC50) |
|---|---|---|---|
| perilipin-5 | Homo sapiens (human) | 4.0045 | |
| perilipin-1 | Homo sapiens (human) | 2.2083 | |
| ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | 2.6045 | |
| melanocortin receptor 4 | Homo sapiens (human) | 1.997 | |
| 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 isoform a | Homo sapiens (human) | 3.5425 | |
| hexokinase HKDC1 | Homo sapiens (human) | 8.99 | |
| Synaptojanin-2 | Homo sapiens (human) | 10 | |
| Solute carrier family 22 member 2 | Homo sapiens (human) | 0.4 | |
| Solute carrier family 22 member 1 | Homo sapiens (human) | 0.21 | |
| Solute carrier family 22 member 3 | Homo sapiens (human) | 0.41 | |
| 72 kDa type IV collagenase | Homo sapiens (human) | 7.63 | |
| Matrix metalloproteinase-9 | Homo sapiens (human) | 7.63 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 0.5 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 0.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bansal, S; Sachdev, R; Sharma, N; Sinha, R; Titiyal, JS | 1 |
| Arnalich-Montiel, F; López-Arencibia, A; Lorenzo-Morales, J; Martín-Navarro, CM; Piñero, JE; Valladares, B | 1 |
| Gil, MH; Moutinho, GM; Santos, LF; Saramago, B; Serro, AP; Silva, D; Sousa, HC | 1 |
3 other study(ies) available for moxifloxacin and chlorhexidine
| Article | Year |
|---|---|
Bilateral microbial keratitis in highly active antiretroviral therapy-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a case series.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amnion; Anti-Bacterial Agents; Antiretroviral Therapy, Highly Active; Aza Compounds; Benzamidines; Carboxymethylcellulose Sodium; Cefazolin; Chlorhexidine; Corneal Ulcer; Drug Therapy, Combination; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pain; Quinolines; Stevens-Johnson Syndrome; Tobramycin; Treatment Outcome; Tropanes; Visual Acuity | 2011 |
Evaluation of the in vitro activity of commercially available moxifloxacin and voriconazole eye-drops against clinical strains of Acanthamoeba.
Topics: Acanthamoeba castellanii; Amebicides; Amphotericin B; Animals; Anti-Bacterial Agents; Antifungal Agents; Aza Compounds; Chlorhexidine; Colorimetry; Drug Combinations; Fluoroquinolones; HeLa Cells; Humans; Macrophages; Mice; Moxifloxacin; Ophthalmic Solutions; Parasitic Sensitivity Tests; Pyrimidines; Quinolines; Triazoles; Voriconazole | 2013 |
Antibacterial layer-by-layer coatings to control drug release from soft contact lenses material.
Topics: Administration, Ophthalmic; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Chlorhexidine; Contact Lenses, Hydrophilic; Cross-Linking Reagents; Delayed-Action Preparations; Diclofenac; Drug Liberation; Excipients; Models, Theoretical; Moxifloxacin; Polyelectrolytes; Tears | 2018 |